Publications for Magnus Janzon
Co-author map based on ISI articles 2007-
Publications mentioned in social media 15 times*
Journal Articles
Martin Henriksson and Magnus Janzon
Cost-effectiveness of ticagrelor in acute coronary syndromes
Expert review of pharmacoeconomics & outcomes research, 2013, 13(1), 9-18.
|
Thomas Davidson, Magnus Husberg, Magnus Janzon, Jonas Oldgren and Lars-Åke Levin
Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
European Heart Journal, 2013, 34(3), 177-183.
Web of Science® Times Cited: 1 |
Elisabet Nikolic, Magnus Janzon, Ole Hauch, Lars Wallentin and Martin Henriksson
Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study
European Heart Journal, 2013, 34(3), 220-228.
Web of Science® Times Cited: 2 |
Tim Tödt, Eva Maret, Joakim Alfredsson, Magnus Janzon, Jan Engvall and Eva Swahn
Relationship between treatment delay and final infarct size in STEMI patients treated with abciximab and primary PCI
BMC Cardiovascular Disorders, 2012, 12(9), 1-9.
|
Artur Dziewierz, Waldemar Mielecki, Zbigniew Siudak, Tomasz Rakowski, Magnus Janzon, Ralf Birkemeyer, Wojciech Zasada, Jacek S. Dubiel and Dariusz Dudek
Early abciximab administration before primary percutaneous coronary intervention improves clinical outcome in diabetic patients with ST-segment elevation myocardial infarction (EUROTRANSFER Registry)
Atherosclerosis, 2012, 223(1), 212-218.
|
Tomasz Rakowski, Zbigniew Siudak, Artur Dziewierz, Ralf Birkemeyer, Magnus Janzon, Waldemar Mielecki, Krzysztof Zmudka, Jacek S Dubiel and Dariusz Dudek
Impact of infarct related artery patency after early abciximab administration on one-year mortality in patients with ST-segment elevation myocardial infarction (data from the EUROTRANSFER Registry)
Kardiologia polska, 2012, 70(3), 215-221.
Web of Science® Times Cited: 1 |
Thomas Davidson, Magnus Husberg, Magnus Janzon and Lars-Åke Levin
The Cost of Thromboembolic Events and their Prevention among Patients with Atrial Fibrillation
Journal of Atrial Fibrillation, 2011, 2(4), 00-00.
|
Niklas Ekerstad, Eva Swahn, Magnus Janzon, Joakim Alfredsson, Rurik Löfmark, Marcus Lindenberger and Per Carlsson
Frailty Is Independently Associated With Short-Term Outcomes for Elderly Patients With Non-ST-Segment Elevation Myocardial Infarction
Circulation, 2011, 124(22), 2397-2404.
Fulltext  Web of Science® Times Cited: 13 |
Nathalie Eckard, Magnus Janzon and Lars-Åke Levin
Compilation of cost-effectiveness evidence for different heart conditions and treatment strategies
Scandinavian Cardiovascular Journal, 2011, 45(2), 72-76.
Fulltext |
Sofia Lawesson, Tim Tödt, Joakim Alfredsson, Magnus Janzon, Ulf Stenestrand and Eva Swahn
Gender difference in prevalence and prognostic impact of renal insufficiency in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention
Heart, 2011, 97(4), 308-314.
Fulltext Web of Science® Times Cited: 7 |
Alexander Bufe, Ferrari Emile, Laurent Drogoul, Josep Guindo Soldevila, Di Pasquale Guiseppe, Lettino Maddalena, Magnus Janzon and Ruth E. Brown
Costs of bleeds relating to acute coronary syndrome therapies.
Journal of Medical Economics, 2010, 13(2), 236-240.
|
H Hemingway, Martin Henriksson, R. Chen, J. Damant, N. Fitzpatrick, K. Abrams, A. Hingorani, Magnus Janzon, M. Shipley, G. Feder, B. Keogh, Ulf Stenestrand, K. McAllister, J-C Kaski, A. Timmis, S. Palmer and M. Sculpher
The effectiveness and cost-effectiveness of biomarkers for the prioritisation of patients awaiting coronary revascularisation: a systematic review and decision model.
Health Technology Assessment, 2010, 14(9), .
Web of Science® Times Cited: 8 |
Artur Dziewierz, Zbigniew Siudak, Tomasz Rakowski, Michal Chyrchel, Waldemar Mielecki, Magnus Janzon, Ralf Birkemeyer, Roman M Wojdyla, Jacek S Dubiel and Dariusz Dudek
Early abciximab administration before primary percutaneous coronary intervention improves clinical outcome in elderly patients transferred with ST-elevation myocardial infarction Data from the EUROTRANSFER registry
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2010, 143(2), 147-153.
Web of Science® Times Cited: 3 |
Mikael Aasa, Martin Henriksson, Mikael Dellborg, Lars Grip, Johan Herlitz, Lars-Åke Levin, Leif Svensson and Magnus Janzon
Cost and health outcome of primary percutaneous coronary intervention versus thrombolysis in acute ST-segment elevation myocardial infarction-Results of the Swedish Early Decision reperfusion Study (SWEDES) trial
AMERICAN HEART JOURNAL, 2010, 160(2), 322-328.
Web of Science® Times Cited: 5 |
Tim Tödt, Sofia Sederholm-Lawesson, Ulf Stenestrand, Joakim Alfredsson, Magnus Janzon and Eva Swahn
Early treatment with abciximab in patients with ST elevation myocardial infarction results in a high rate of normal or near normal blood flow in the infarct related artery
Acute cardiac care, 2010, 12(1), 10-17.
|
Zbigniew Siudak, Tomasz Rakowski, Artur Dziewierz, Magnus Janzon, Ralf Birkemeyer, Justyna Stefaniak, Lukasz Partyka, Krzysztof Zmudka and Dariusz Dudek
Early abciximab use in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention improves long-term outcome. Data from EUROTRANSFER Registry
KARDIOLOGIA POLSKA, 2010, 68(5), 539-545.
Web of Science® Times Cited: 11 |
Martin Henriksson, Jacqueline Damant, Natalie K Fitzpatrick, Keith Abrams, Aroon D Hingorani, Ulf Stenestrand, Magnus Janzon, Gene Feder, Bruce Keogh, Martin J Shipley, Juan-Carlos Kaski, Adam Timmis, Mark Sculpher and Harry Hemingway
Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery
BRITISH MEDICAL JOURNAL, 2010, 340, .
Web of Science® Times Cited: 15 |
Ulla Walfridsson, Anna Strömberg, Magnus Janzon and Håkan Walfridsson
Wolff-Parkinson-White Syndrome and Atrioventricular Nodal Re-Entry Tachycardia in a Swedish Population: Consequences on Health-Related Quality of Life
Pacing and Clinical Electrophysiology, 2009, 32(10), 1299-1306.
Web of Science® Times Cited: 4 |
J Knot, P Widimsky, W Wijns, Ulf Stenestrand, SD Kristensen, A Van´T Hof, F Weidinger, Magnus Janzon, BL Nörgaard, JT Soerensen, van de Wetering, K Thygesen, PA Bergsten, C Digerfeldt, A Potgieter, N Tomer and Fajadet
How to set up an effective national primary angioplasty network: Lessons learned from five European countries
EuroIntervention, 2009, 3(299), 301-309.
Web of Science® Times Cited: 19 |
Tomasz Rakowski, Zbigniew Siudak, Artur Dziewierz, Ralf Birkemeyer, Jacek Legutko, Waldemar Mielecki, Rafal Depukat, Magnus Janzon, Justyna Stefaniak, Krzysztof Zmudka, Jacek S Dubiel, Lukasz Partyka and Dariusz Dudek
Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER Registry
AMERICAN HEART JOURNAL, 2009, 158(4), 569-575.
Web of Science® Times Cited: 24 |
Urban Alehagen and Magnus Janzon
A clinician’s experience of using the Cardiac Reader NT-proBNP point-of-care assay in a clinical setting
European Journal of Heart Failure, 2008, 10(3), 260-266.
Fulltext Web of Science® Times Cited: 5 |
Dariusz Dudek, Zbigniew Siudak, Magnus Janzon, Ralf Birkemeyer, Guillermo Aldama-Lopez, Corrado Lettieri, Bogdan Janus, Andrzej Wisniewski, Sergio Becrti, Zoran Olivari, Tomasz Rakowski, Lukasz Partyka, Jochen Goedicke and Krzysztof Zmudka
European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus an early administration of abciximab-EUROTRANSFER Registry
American Heart Journal, 2008, 156(6), 1147-1154.
Web of Science® Times Cited: 34 |
Magnus Janzon, Lars-Åke Levin and Eva Swahn
Invasive treatment in unstable coronary artery disease promotes health-related quality of life: results from the FRISC II trial
American Heart Journal, 2004, 148(1), 114-121.
Web of Science® Times Cited: 17 |
Magnus Janzon, Lars-Åke Levin and Eva Swahn
Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial
Heart, 2003, 89(3), 287-292.
Web of Science® Times Cited: 4 |
Magnus Janzon, Lars-Åke Levin and Eva Swahn
Cost-effectiveness of an invasive strategy in unstable coronary artery disease: results from the FRISC II invasive trial
European Heart Journal, 2002, 23(1), 31-40.
Web of Science® Times Cited: 26 |
Books
Conference Articles
Staffan Nilsson, Pär Andersson, Magnus Janzon, Jan-Erik Karlsson and Lars Borgquist
Efficiency of point-of-care Troponin-T testing in a Swedish primary care setting
European Primary Care Cardiovascular Society 4th Annual Scientific Meeting, September 1-2, 2011, Berlin, Germany, 2011.
|
M. Henriksson, Elisabet Nikolic, Magnus Janzon, O. Hauch, Lars-Åke Levin and L. Wallentin
LONG-TERM COSTS AND HEALTH OUTCOMES OF TREATING ACUTE CORONARY SYNDROME PATIENTS WITH TICAGRELOR BASED ON THE EU LABEL - COST-EFFECTIVENESS ANALYSIS BASED ON THE PLATO STUDY in VALUE IN HEALTH, vol 14, issue 3, pp A40-A40
VALUE IN HEALTH, 2011.
Web of Science® Times Cited: 2
|
Magnus Janzon, Elisabet Nikolic, Martin Henriksson, Lars-Åke Levin, Ole Hauch, DB Mark, P. Cowper, P. Kaul, RA. Harrington, J. Horrow and Lars Wallentin
Health Economics in the PLATelet Inhibition and Patient Outcomes (PLATO) Randomized Trial: Report on Within Trial Resource Use Patterns
The American Heart Association 2010 Scientific Sessions, Chicago, IL, USA, November 13-17 2010, 2010.
|
Z Siudak, R Birkemeyer, T Rakowski, A Dziewierz, Magnus Janzon, J Skowronek, P Ranosz, J S Dubiel and D Dudek
Out-of-hospital cardiac arrest in patients treated with primary PCI for STEMI. Long-term follow up data from EUROTRANSFER registry in EUROPEAN HEART JOURNAL, vol 31, issue , pp 900-900
EUROPEAN HEART JOURNAL, 2010.
|
Nathalie Eckard, Magnus Janzon and Lars-Åke Levin
Communicating cost-effectiveness ratios to decision makers - the case of the Swedish national guidelines for hearts diseases (Abstract)
Value in Health, 2010.
|
Nathalie Eckard, Magnus Janzon and Lars-Åke Levin
Communicating cost-effectiveness ratios to decision makers - the case of the Swedish national guidelines for heart diseases (Poster)
ISPOR 13th Annual European Congress. Prag Tjeckien, 2010.
|
Thomas Davidson, Magnus Husberg, Magnus Janzon and Lars-Åke Levin
The cost of atrial fibrillation in Sweden (Poster)
Value in Health, 2010.
|
Eva Maret, Lars Brudin, Magnus Janzon, J Ohlsson and Jan Engvall
High sensitivity and specificity for detecting transmural infarction with a feature tracking software on cine MRI.
ESC Barcelona 2009, 2009.
|
Harry Hemingway, Ruoling Chen, Jacqueline Damant, Natalie Fitzpatrick, Aroon Hingorani, Bruce Keogh, Kate McAllister, Martin Henriksson, Keith Abrams, Magnus Janzon, Ulf Stenestrand, Juan-Carlos Kaski, Adam Timmis, Stephen Palmer and Mark Sculpher
Cost-effectiveness of circulating biomarkers in managing stable coronary disease.
SMDM,2008, 2008.
|
Stella Cizinsky, Rurik Löfmark and Magnus Janzon
Etik och hälsoekonomi, när bot inte längre är möjligt
Fortbildningsdagar i Kardiologi,2008, 2008.
|
Zahar Shakeri, Malin Hammar-Henriksson, Joakim Alfredsson and Magnus Janzon
Evaluating cardiodetect with card test for early diagnosis of acute myocardial infarction.
X Svenska Kardiovaskulära Vårmöte,2008, 2008.
|
Tomasz Rakowski, Artur Dziewierz, Zbigniew Siudak, Waldemar Mielecki, Jacek Legutko, Magnus Janzon, Ralf Birkemeyer, Rafal Depukat and Dariusz Dudek
Early Abciximab administration before primary percutaneous coronary interventions reduces mortality but not in low-risk patients. Results from EUROTRANSFER registry on ST-elevation myocardial infarction patients.
ACC - 57th Annual Scientific Session,2008, 2008.
|
W Mielecki, Z Siudak, T Rakowski, A Dziewierz, Magnus Janzon, R Birkemeyer, D Dykla, J Zdzienicka and D Dudek
Early abcizimab administration before primary angioplasty influences 30-day clinical outcome in diabetic patients with ST-elevation myocardial infarction
ESC Congress,2008, 2008.
|
Z Siudak, Magnus Janzon, R Birkemeyer, T Rakowski, A Dziewierz, P Kleczynski, W Mielecki and D Dudek
Radial approach in STEMI patients treated with primary PCI with abciximab is safer than femoral in terms of local access site complications. Date from EUROTRANSFER registry.
ESC Congress,2008, 2008.
|
Helene Zachrisson, Anders Persson, Jan Engvall, Ulf Stenestrand and Magnus Janzon
CT angiography - clinical experience from Linköping University Hospital
X Svenska Kardiovaskulära Vårmötet,2008, 2008.
|
Jacek Legutko, Tomasz Rakowski, Zbigniew Siudak, Lukasz Rzeszutko, Magnus Janzon, Ralf Birkemeyer, Pawel Kleczynski and Dariusz Dudek
Efficacy and safety of early clopidogrel administration with or without Abciximab in patients with ST-segment elevation myocardial infarction transferred for primary PCI. Results from the EUROTRANSFER registry.
ACC - 57th Annual Scientific Session,2007, 2008.
|
Zbigniew Siudak, Tomasz Rakowski, Artur Dziewierz, Wojciech Zasada, Michal Brzezinski, Magnus Janzon, Ralf Birkemeyer and Darius Dudek
Primary percutaneous coronary intervention performed during nightshift hours was associated with increased in-hospital mortality in patients with ST elevation myocardial infarction. Results from EUROTRANSFER registry.
ACC - 57th Annual Scientific Session,2008, 2008.
|
Joakim Alfredsson, Anna Käll, Hanna Tilander, Magnus Janzon, Eva Swahn and Lena Jonasson
Sex matters-lipid goal achievement in a population admitted to a coronary care unit
X Svenska Kardiovaskulära Vårmötet,2008, 2008.
|
Martin Henriksson, Magnus Janzon, M. Aasa, Elisabet Lundborg (Nikolic), L. Svensson, J. Herlitz, L. Grip and Lars-Åke Levin
Cost-effectiveness of very early treatment strategies for acute ST-elevation myocardial infarction based on the Swedish early decision (SWEDES) reperfusion trial (oral presentation)
SMDM Europe,2008, 2008.
|
Zbigniew Siudak, Artur Dziewierz, Tomasz Rakowski, Sergio Berti, Zoran Olivari, Magnus Janzon, Ralf Birkemeyer and Dariusz Dudek
By-passing Emergency Room Shortens Time Delays in STEM I Patients Transferred for Primary PCI. Results From EUROTRANSFER Registry, Washington DC, USA
AMERICAN JOURNAL OF CARDIOLOGY,ISSN 0002-9149, Transcatheter Cardiovascular Therapeutics Abstracts, 2008.
Web of Science® Times Cited: 1
|
Zbigniew Studak, Tomasz Rakowski, Artur Dziewierz, Magnus Janzon, Ralf Birkemeyer, Sergio Berti, Lukasz Partyka, Krzysztof Zmudka and Dariusz Dudek
Primary PCI Performed With Delay > 90 Minutes From Diagnosis Seems Acceptable in Terms of Short- and Long-Term Clinical Outcome. One Year Results From EUROTRANSFER Registry,Washington DC, USA
AMERICAN JOURNAL OF CARDIOLOGY,ISSN 0002-9149 Transcatheter Cardiovascular Therapeutics Abstracts, 2008.
|
Magnus Janzon
EUROTRANSFER and beyond - There is still a rationale for facilitation!
ACS Network Workshop,2007, 2007.
|
Magnus Janzon
STEMI treatment in the real world: Learning from RIKS-HIA and EuroTransfer
PACS. Progress in Acute Coronary Syndromes,2007, 2007.
|
Dariusz Dudek, Zbigniew Siudak, Magnus Janzon, Ralf Birkemeyer, Krzysztof Zmudka, Roberto Zanini, Zoran Olivari, Sergio Berti and Leonardo Bolognese
Primary PCI performed with delay <120 minutes from diagnosis seems acceptable in terms of short-term clinical outcomes. Results from EUROTRANSFER registry.
LCT,2007, 2007.
|
Magnus Janzon
Grunder i hälsoekonomi. Exempel från kardiologin.
Nationella fortbildningsdagar i kardiologi.,2007, 2007.
|
Dariusz Dudek, Zbigniew Siudak, Magnus Janzon, Ralf Birkemeyer, Krzysztof Zmudka, Corrado Lettieri, Guillermo Aldama, Andrzej Wisniewski, Bogdan Janus and Lukasz Partyka
Determinants of outcomes in patients with ST elevation myocardial infarction (STEMI) transferred for primary PCI. Results from the EUROTRANSFER registry.
ESC,2007, 2007.
|
Dariusz Dudek, Zbigniew Siudak, Magnus Janzon, Ralf Birkemeyer, Krzysztof Zmudka, Corrado Lettieri, Guillermo Aldama, Andrzej Wisniewski, Bogdan Janus and Lukasz Partyka
EUROTRANSFER Registry. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion (PCI) with a special focus on upstream use of abciximab.
ESC,2007, 2007.
|
Magnus Janzon
Novel Strategies for the Management of STEMI
Kardiologen, US som ett led i vår utmärkelse Center of Excellence Europé 2007 möte med läkare från Holland,2007, 2007.
|
Ulla Walfridsson, Anna Strömberg, Magnus Janzon and Håkan Walfridsson
Paroxysmal supraventricular tachyarrhythmia in a Swedish population: consequences on health-related quality of life
European Society of Cardiology 2007,2007, 2007.
|
Magnus Janzon, Mikael Aasa, Johan Lyth, Leif Svensson, Johan Herlitz, Lars Grip and Lars-Åke Levin
Cost and effectiveness comparison of very early treatment with primary percutaneous coronary intervention facilitated with abciximab or thrombolytic therapy for acute ST-elevation myocardial infarction
ACC,2007, 2007.
|
Magnus Janzon
Prehospital treatment - the role of thrombolytics, GPIIb/IIIa antagonists och thienopyridines?
1st Pan-European STEMI Network Symposium,2007, 2007.
|
Magnus Janzon
Antitrombotisk behandling prehospitalt vid primär PCI
IX Svenska Kardiovaskulära Vårmötet,2007, 2007.
|
Magnus Janzon, Lars-Åke Levin and Eva Swahn
Invasive treatment in non ST elevation acute coronary syndorme promotes long-term health related quality of life - results from the FRISC II trial
ACC, New Orleans, LA,2007, 2007.
|
Magnus Janzon
STEMI - Primär PCI Östgötamodellen. Uppbyggnad och resultat.
Nationellt Thoraxmöte i Linköping,2006, 2006.
|
Magnus Janzon
Bröstsmärtor på akuten, akut koronart syndorm. Vad ska göras, när?
Nationellt Akutläkarmöte i Linköping,2006, 2006.
|
Magnus Janzon
Den kostnadseffektiva revaskulariseringen, finns den?
VIII Svenska Kardiovaskulära Vårmötet,2006, 2006.
|
Ioan Liuba, Magnus Janzon, Ulla Walfridsson and Håkan Walfridsson
Impact of catheter ablation on health related quality of life in patients with focal atrial tachycardia
VIII Svenska Kardiovaskulära Vårmötet,2006, 2006.
|
Magnus Janzon
Hälsoekonomiska och sjukvårdsrelaterade synpunkter vid antitrombotisk behandling vid kranskärlssjukdom
VIII Svenska Kardiovaskulära Vårmötet,2006, 2006.
|
Jan Wigren, Christer Carlsson, Ingela Johansson, Magnus Janzon and Anders Broström
Patient´s perceptions of prehospital care during acute myocardial infarction
NSFS Landsgruppe av Kardiologiske sykepleiere,2006, 2006.
|
Martin Henriksson, Anders Nordlund, Magnus Janzon and Eva Swahn
A comparison of EQ-5D and SF-6D utilities
iHEA 2003, San Francisco. Muntlig posterpresentation,2003, 2003.
|
Magnus Janzon, Martin Henriksson, Lars-Åke Levin and Eva Swahn
Quality of life in unstable angina - Individual and public preferences differ in levels but are similar when measuring changes over time
European Heart Journal, 2002.
|
Magnus Janzon, Martin Henriksson, Lars-Åke Levin and Eva Swahn
Quality of life in unstable angina. Individual and public preferences differ in levels but are similar when measuring changes over time
ISTAHC-konferens, Berlin, juni 2002,2002, 2002.
|
Magnus Janzon, Lars-Åke Levin and Eva Swahn
Cost-effectiveness of early invasive treatment in unstable coronary artery disease: A one-year follow-up from the FRISC II invasive trial
Journal of the American College of Cardiology, 2001.
Web of Science® Times Cited: 1
|
Magnus Janzon, Lars-Åke Levin and Eva Swahn
Quality of life one year after invasive intervention in unstable coronary artery disease: Results from the FRISC II invasive trial
Journal of the American College of Cardiology, 2001.
|
Magnus Janzon, Lars-Åke Levin and Eva Swahn
Cast-comparison of early invasive versus non-invasive treatment in unstable coronary artery disease - A six months follow-up from the FRISC II invasive trial
Journal of the American College of Cardiology, 2000.
|
Magnus Janzon, Lars-Åke Levin and Eva Swahn
Quality of life in unstable coronary artery disease - A comparison of early invasive versus non-invasive treatment. Six months follow-up from the FRISC II invasive trial
Journal of the American College of Cardiology, 2000.
|
L Wallentin, E Diderholm, Magnus Janzon, F Kontny, B Lagerqvist, B Lindahl, S Husted and Eva Swahn
The protective effects of long-term lmw heparin (dalteparin) treatment in unstable CAD is confined to patients not previously treated with statins
European Heart Journal, 2000.
|
L Wallentin, E Diderholm, Magnus Janzon, F Kontny, B Lagerqvist, S Husted and Eva Swahn
Elevation of LDL cholesterol and interaction with the cholesterol lowering effect of statins during long-term low-molecular-weight heparin (dalteparin) treatment
European Heart Journal, 2000.
|
Ph.D. Theses
Reports
* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.
Ph.D., Lic. Theses
